Research by Travis Donahoe PhD '23 finds that enforcement actions targeting suppliers that profit from the opioid crisis, rather than the vulnerable individuals swept up in it, are a critical way to stem the tide of addiction and death.
Federally funded research by Harvard scholars has led to life-changing solutions to real-world problems facing millions of Americans, from preventing opioid deaths to treating diseases to building a better air conditioner.
Alberto Ascherio MPH ’89, DPH ’92 was honored for work establishing a link between Epstein-Barr virus and multiple sclerosis, Joel Habener for contributions to the development of GLP-1 drugs, and David Liu for the development of the gene editing platforms.
A Harvard patient-scientist and her husband are among the researchers behind a gene-editing technique that could lead to a treatment for a handful of rare, fatal disorders caused by misfolded proteins in the brain.
Inspired by his experience with malaria as a child in Ghana, Wyss Institute scientist Kwasi Adu-Berchie SM ’18, PhD ’22 is working to make health care more equitable globally.
As a graduate student, Rob Devlin PhD ’17 helped develop an innovative mini-lens. Now he runs a startup that produces millions of the devices for use in an array of consumer electronics.
Three Harvard Medical School research teams received Blavatnik Therapeutics Challenge Awards to pursue novel approaches to medical challenges, offering potential solutions to people affected by Fragile X syndrome, oxygen deprivation, and Parkinson’s disease.
A biotechnology startup launched out of a Harvard chemistry lab is developing new antibiotic compounds that show promise in treating drug-resistant infections and diseases.
Harvard Medical School researchers paired a genetic insight with gene editing technology to create a life-changing new therapy for sickle cell disease.
